Tattoo Numbing: What Science Knows, What Artists Observe and What the Market Cannot Prove

Topical anesthetics can reduce surface pain. Whether they help a session, change the working surface or affect saturation is a different question — and the evidence is thinner than the marketing.

Tattoo numbing has become one of the industry’s most confident conversations built on one of its least complete bodies of evidence.

Clients say it helped them sit longer. Other clients say it did almost nothing—or that the pain felt worse when the effect ended.

Some artists say numbing products make difficult sessions possible. Others describe skin that feels swollen, rubbery, pale, overhydrated or harder to work. Manufacturers promise fast onset, hours of relief and no effect on ink. Global sales continue to rise.

All four observations can exist at the same time.

They are not, however, the same kind of evidence.

The right question is not simply:

Does tattoo numbing work?

It is:

What does a topical anesthetic reliably do, what might it change during tattooing, and which claims are supported by evidence rather than repetition?

That distinction matters because tattoo numbing products sit at the intersection of a drug, a cosmetic procedure, a professional technique and a deeply subjective experience. Every part of that sentence changes the answer.

The short answer

Topical anesthetics can reduce superficial procedural pain. Lidocaine and related local anesthetics block voltage-gated sodium channels, temporarily reducing nerve-signal transmission in the treated tissue. Evidence from dermatologic procedures supports that basic mechanism and analgesic effect.

Tattoo-specific clinical evidence is limited. Research on injections, lasers, microneedling and other skin procedures can inform tattooing, but it does not directly prove how a particular product affects a six-hour color tattoo, linework, saturation or the final recovered result.

The product is more than its active percentage. Vehicle, dose, surface area, application time, occlusion, other active ingredients, skin condition and whether the barrier is intact all affect performance and risk.

Artist observations matter—but they are not controlled trials. Reports of texture change, swelling, stencil problems or difficult saturation are legitimate practice observations. They do not prove that every properly formulated lidocaine product causes those effects.

Sales prove demand, not performance. A growing market tells us that clients want pain-management options. It cannot establish that the products are safe, compliant, effective for tattooing or neutral to tattoo quality.

A better evidence system

Throughout this article, we separate four categories:

The industry gets into trouble when one column is presented as another.

What topical anesthetics actually do

Voltage-gated sodium channels: Tiny gates in the wall of a nerve fibre that open to let sodium in and carry an electrical signal along the nerve. Lidocaine temporarily blocks them, so the signal — including the one your brain reads as pain — is weakened or stopped in the treated area.

Pain signals depend on electrical activity traveling along sensory nerves. Lidocaine temporarily blocks voltage-gated sodium channels, reducing the nerve’s ability to conduct those signals.

That mechanism is established pharmacology. It is why topical lidocaine is used across multiple medical and dermatologic contexts.

What is less predictable is the degree of relief in one person at one tattoo appointment.

Effectiveness depends on more than “4%” or “5%”

Two products with the same labeled lidocaine concentration can perform differently because the active ingredient still has to leave the formula, cross the outer skin barrier and reach superficial nerve endings.

Relevant variables include:

• the chemical form of lidocaine;
• the cream, gel, spray or other delivery vehicle;
• penetration-enhancing ingredients;
• how much is applied;
• the size of the treated area;
• contact time;
• whether the area is covered;
• skin thickness, condition and hydration;
• anatomical location;
• whether the skin remains intact.

This is why concentration is important but insufficient. A larger number on the package is not a complete measure of effectiveness—and can move a product outside legal OTC conditions while increasing safety risk.

Cream and spray are not automatically interchangeable

A cream can remain on the skin longer and create sustained contact. A spray can distribute a lighter film more quickly. Neither format is inherently stronger.

The formulation determines delivery. The directions determine exposure. The condition of the skin determines absorption.

A pre-procedure product applied to intact skin is also not scientifically or legally interchangeable with a spray promoted for repeated application after tattooing has begun. Once the barrier is disrupted, absorption and exposure conditions change.

What the science says about pain relief

Systematic reviews of randomized trials support topical anesthetics for reducing pain during various forms of dermal instrumentation. But the studies differ by product, procedure, application time and endpoint. Results from a needle insertion or laser procedure should not be converted into a precise promise about an entire tattoo session.

The defensible conclusion is narrower:

A correctly formulated and appropriately used topical anesthetic can reduce superficial procedural pain for some period of time. It may reduce discomfort; it does not guarantee a painless tattoo.

That qualification matters. Tattooing is repetitive. A session can move across differently innervated tissue, last for hours and include lining, shading, wiping and reworking an increasingly irritated surface. Most clinical studies do not reproduce that full experience.

Onset and duration are not universal numbers

Manufacturers often advertise one onset time and one duration as if both were product constants. They are not.

How quickly numbness begins and how long it lasts depend on dose, vehicle, contact time, anatomy, skin properties and the procedure. Studies of lidocaine/prilocaine formulations have also shown that inadequate contact time may produce insufficient dermal anesthesia.

Claims such as “works in ten minutes,” “lasts four hours” or “pain-free” require evidence for the exact product and exact conditions of use. A testimonial cannot substantiate a universal duration claim.

When the numbness ends

Clients sometimes describe a “wall” of pain when a numbing product wears off. Pharmacologically, lidocaine does not create extra tattoo pain as a rebound mechanism in the same way that some drugs produce physiological withdrawal. The experience can still feel abrupt: reduced sensation is replaced by the full sensation of tattooing on tissue that has already been worked.

That is a credible client experience. It should not be casually converted into the scientific claim that topical lidocaine makes later pain biologically worse.

What artists say—and what those observations may mean

There is no representative global survey establishing one unified artist position on numbing products. Statements such as “artists hate numbing cream” or “most artists now approve it” are usually built from selective interviews, social media and studio culture.

The more useful approach is to identify the recurring observations and ask what could plausibly produce them.

“The skin becomes rubbery or difficult to stretch”

Occlusion: Covering the skin with something that stops water and product escaping — plastic wrap, a film or a heavy base. It increases hydration of the outer layer and increases how much of a product is absorbed.

Some artists report a change in tissue feel after a numbing cream has been applied and covered. Possible contributors include prolonged occlusion, hydration of the stratum corneum, the formula’s base, local irritation or swelling.

That does not prove lidocaine itself makes skin rubbery. It does support an important operational point: the full formula and application method can change the working surface, even when the active anesthetic performs as intended.

“The skin looks pale, red or swollen”

Color change can result from pressure, occlusion, irritation, temperature, the formula vehicle or vasoactive ingredients. Lidocaine should not be treated as synonymous with epinephrine; epinephrine is a vasoconstrictor with a different role and a different regulatory profile.

A small controlled study of topical lidocaine/prilocaine on intact forearm skin found no meaningful change in tested vasodilator or vasoconstrictor responses. That finding argues against declaring that all topical anesthesia necessarily impairs cutaneous blood flow. It also does not rule out temporary visual or textural changes from a particular formula or application protocol.

“The stencil will not hold”

Residual cream, oil or other film can interfere with cleansing, drying or stencil transfer. That is a surface-preparation issue, not evidence that sodium-channel blockade chemically destroys a stencil.

The artist needs to know what was applied, when it was applied and whether it can be completely removed before professional skin preparation.

“The skin will not take ink”

This is the most important claim—and the least directly studied.

We found no adequate tattoo-specific clinical trial demonstrating that a compliant topical lidocaine product, used on intact skin as directed, either improves or impairs pigment deposition, color saturation or long-term retention.

Artist difficulty can still be real. If skin is swollen, overhydrated, irritated or covered in residue, it may handle differently. But “the skin was difficult to work” and “lidocaine prevents ink from entering the dermis” are not equivalent statements.

The first is professional observation. The second is a causal biological claim that requires direct evidence.

Does numbing affect ink packing?

Ink packing is not one standardized laboratory event. It describes an artist repeatedly depositing pigment to create solid, even saturation. The outcome depends on needle configuration, machine settings, hand speed, stretch, depth, pigment dispersion, skin response and the number of passes.

A numbing product could influence the session indirectly if it changes:

• surface residue and stencil preparation;
• tissue hydration or swelling;
• the artist’s ability to stretch the skin;
• visible bleeding or redness;
• client movement;
• session tolerance and available working time.

That produces two competing possibilities.

First, better client comfort may reduce flinching, muscle tension and unscheduled breaks. For an artist, a more stable client can make precise work easier.

Second, a poorly tolerated or poorly removed formula may change the working surface enough to make technique less predictable.

Both are plausible. Neither supports the blanket claim that numbing always helps or always hurts ink packing.

What we will—and will not—claim

The claim we are prepared to stand behind is:

Designed to provide temporary surface-level comfort when used as directed. Discuss use with your artist before the appointment.

Until the exact formula has been directly tested under controlled tattoo conditions, we will not claim that it:

• does not interfere with ink flow;
• improves ink saturation;
• helps artists pack color;
• preserves line precision;
• allows longer sessions;
• works on broken skin;
• delivers pain-free tattooing.

Those claims move beyond established ingredient mechanism into product-specific tattoo performance or unapproved use.

Color versus black-and-gray: does numbing matter more?

There is no credible clinical evidence that lidocaine interacts differently with black pigment than with a colored tattoo pigment simply because of pigment color.

The practical difference is procedural.

Why color can feel different

Solid color work may require repeated passes and dense, uniform saturation. Multiple colors can require repeated wiping and work across adjacent areas. Large-scale color realism, traditional color and blackout-style saturation can create very different demands, but all can involve prolonged work on the same region.

If a client benefits from numbing, the value may come from tolerating repeated passes—not from a special chemical relationship between anesthetic and color pigment.

Why black-and-gray is not automatically easier

Black-and-gray can involve fine lining, whip shading, smooth gradients, deep saturation or extensive coverage. A delicate fine-line tattoo and a blacked-out panel both use black pigment but have radically different procedural demands.

“Color hurts more” and “black-and-gray does not need numbing” are cultural shortcuts, not scientific rules.

The honest conclusion

Pain burden relates more closely to technique, duration, placement, repeated passes and individual sensitivity than to whether the bottle contains black or colored pigment.

Likewise, any effect on the working surface is more likely to be driven by formula and application conditions than by pigment color.

Location on the body

Tattoo pain maps are popular because they are simple. Human pain is not.

Location matters because body regions differ in nerve distribution, tissue thickness, proximity to bone, movement, pressure and individual sensitivity. Yet there is no universally validated tattoo pain chart that predicts one person’s experience from placement alone.

Artists and clients often report greater discomfort in areas such as the ribs, sternum, feet, hands, knees, elbows, neck and other regions with limited soft tissue or high sensitivity. Outer arms, thighs and calves are often described as more manageable. These are useful expectations, not guaranteed rankings.

Location also changes safety

The safety issue is not only how much the area hurts. It is how much product is used, over how much surface area, for how long and on what type of tissue.

Absorption can become more concerning when a topical anesthetic is:

• used over a large tattoo area;
• applied heavily;
• left on for longer than directed;
• covered in a way that increases absorption;
• exposed to heat;
• applied to irritated or barrier-disrupted skin;
• reapplied repeatedly;
• used near eyes, mucous membranes or other high-risk sites.

A large back piece is not merely a small tattoo multiplied. Surface area changes drug exposure.

What clients say

Client reports consistently fall into several patterns:

1. Meaningful early relief: the first portion of the session feels substantially easier.
2. Partial relief: sharp sensation becomes pressure or a more tolerable discomfort.
3. Uneven relief: some parts of the treated area feel numb while others do not.
4. Short duration: the effect ends before the tattoo does.
5. Minimal effect: the product does not provide enough relief to matter.
6. Application reaction: burning, redness, itching or swelling occurs before tattooing begins.
7. Psychological value: knowing an option exists reduces anticipatory anxiety even when pain is not eliminated.

These reports matter because pain is a subjective outcome. But online reviews are highly vulnerable to selection bias, counterfeit product, inconsistent use, undisclosed formula differences and expectation effects.

“Thousands of five-star reviews” is a commercial signal. It is not a controlled efficacy study.

What global sales actually tell us

Commercial research firms describe the broader lidocaine-cream and topical-anesthetic markets as growing, with cosmetic and dermatologic procedures among the demand drivers. Some reports also define a narrower “tattoo numbing cream market.”

The exact figures should be treated cautiously.

Market estimates vary because reports may combine prescription products, general OTC analgesics, cosmetic-procedure anesthetics, tattoo products, creams, gels, sprays and medical uses. Public summaries rarely provide enough underlying sales data to audit the number.

The defensible conclusion is not a precise global tattoo-numbing revenue figure. It is this:

Demand for topical numbing is commercially significant and expanding across cosmetic procedures, including tattooing.

Sales can tell us that clients want more control over procedural discomfort, that e-commerce has reduced friction and that pain tolerance is becoming less culturally tied to proving toughness.

Sales cannot tell us:

• whether the products are legally marketed;
• whether label concentrations are accurate;
• whether the formulas are clinically tested for tattooing;
• whether the products affect recovered tattoo quality;
• whether higher concentration is safer or better;
• whether reviews reflect authentic products.

The market has validated the problem. It has not validated every solution.

The current regulatory reality in the United States

Tattoo numbing products are not ordinary cosmetics when they claim to reduce pain or affect sensation. Those claims make them drugs under U.S. law.

The 4% boundary

OTC monograph: FDA’s rulebook for a category of over-the-counter drugs. A product that follows it exactly — permitted active ingredient, concentration, directions, warnings and claims — can be sold without individual FDA approval. Step outside any of those conditions and it no longer qualifies.

FDA’s OTC external-analgesic framework permits lidocaine within a specified concentration range up to 4% under applicable monograph conditions. In March 2024, FDA warned consumers to avoid certain topical pain-relief products marketed for cosmetic procedures and issued warning letters to six companies. The agency specifically advised consumers not to use OTC topical pain products containing more than 4% lidocaine.

FDA highlighted the risks of high concentration, large treated areas, irritated or broken skin, prolonged application and covering the treated area. Potential severe outcomes include irregular heartbeat, seizures and breathing difficulty.

Enforcement did not stop in 2024

In February 2025, FDA issued further warning letters to tattoo-numbing sellers, including one covering products labeled with 5% lidocaine and tattoo-related indications. FDA stated that the products exceeded the 0.5%–4% lidocaine range in the external-analgesic monograph and that indications related to tattooing and piercing were not included in that monograph.

That last point is easy to miss: a product can sit at or below 4% lidocaine and still have a compliance problem if its claims, combinations, labeling or conditions of use do not conform.

“FDA registered” is not “FDA approved”

Facility registration, establishment listing, product listing and compliance with an OTC monograph are different concepts from FDA approval of a specific product for a specific tattoo indication.

Brands should not use administrative status to imply that FDA has reviewed and approved a tattoo-numbing claim when it has not.

Applying before tattooing versus during tattooing

Our safety direction is the more defensible one: external use on intact skin before tattooing, consistent with the Drug Facts label; not routine application to skin that is already broken, blistered, infected or abnormally irritated.

Marketing a spray for repeated mid-session use on freshly tattooed skin presents a materially different absorption and regulatory question. It should not be treated as a simple extension of intact-skin directions.

Global regulation is not harmonized

Lidocaine status, permitted concentration, supply channel and approved indications differ by jurisdiction. A formula sold OTC in one country may be pharmacy-only, prescription-only or noncompliant in another.

The European Union does not treat a pain-relief claim as an ordinary cosmetic claim. The United Kingdom also distinguishes medicine supply and professional-use conditions. Australia, Canada and other markets apply their own medicine classifications and labeling requirements.

For a global brand, “legal somewhere” is not a market-access strategy. Each target jurisdiction requires a product-classification, formula, label, claims and channel review.

The safety issue the industry understates

Lidocaine toxicity is not an abstract technicality. Systemic exposure can affect the central nervous and cardiovascular systems.

Possible warning symptoms can include:

• numbness or tingling around the mouth;
• metallic taste;
• ringing in the ears;
• dizziness or blurred vision;
• agitation, confusion or muscle twitching;
• abnormal heart rhythm;
• seizure;
• breathing difficulty or loss of consciousness.

Severe or systemic symptoms require emergency medical care.

Risk depends on more than the percentage printed on the bottle. Total dose, body size, application area, skin integrity, time, occlusion, repeat application, other lidocaine-containing products, health conditions and medication interactions all matter.

This is why “strongest numbing cream” is the wrong consumer goal. The useful goal is adequate temporary relief within validated and lawful conditions of use.

Other ingredients deserve scrutiny too

Consumers tend to focus on lidocaine and treat the rest of the formula as background. The rest of the formula can determine both delivery and tolerability.

Menthol, camphor, clove oil, wintergreen-derived ingredients, witch hazel and botanical extracts may create sensory effects or support the product experience. They can also irritate some individuals, contribute to the total active-ingredient analysis or complicate product claims.

“Botanical” does not mean pharmacologically inactive. “Natural” does not mean compatible with every skin type or every condition of use.

Responsible product language distinguishes the legally declared active ingredient from inactive formulation ingredients, and does not imply that botanicals treat inflammation, prevent infection or improve tattoo outcomes without product-specific substantiation.

Where The Numbing Spray fits

The Numbing Spray uses 4% lidocaine as its declared topical-anesthetic active ingredient in a lightweight spray format. The formula also contains ingredients including witch hazel, menthol, camphor, clove, rosemary, turmeric and aloe.

Its responsible position is narrow by design:

• an optional pre-appointment comfort aid;
• applied to intact skin only, according to the Drug Facts label;
• discussed with the artist before use;
• removed completely before professional skin preparation;
• never presented as a guarantee of a pain-free appointment;
• never presented as proven to improve saturation, session length or tattoo quality;
• not promoted for routine application to freshly broken skin.

The 4% lidocaine concentration aligns with the upper U.S. OTC monograph concentration boundary, but Ancient Ink does not treat that number as a substitute for compliant labeling, appropriate use or product-specific substantiation. Every claim still has to earn its place.

Fact, fiction and the honest middle

The Ancient Ink position

Pain tolerance is not a measure of character. Wanting a more manageable appointment does not make a client less committed to the work.

At the same time, comfort should not be sold through exaggerated efficacy, undisclosed tradeoffs or casual use of a pharmacologically active ingredient.

Our position is straightforward:

1. A numbing product is an optional aid, not a requirement.
2. The artist must be part of the decision before appointment day.
3. The active concentration, complete formula and directions all matter.
4. Intact and barrier-disrupted skin are not interchangeable use conditions.
5. Pain relief does not automatically prove neutral tattoo performance.
6. Artist observations should be respected and accurately labeled as professional experience.
7. Client reports should inform better questions, not substitute for controlled evidence.
8. Regulatory compliance is part of product performance.

Ancient Ink’s approach is not to pretend the debate is settled. It is to identify which part is settled, which part remains observational and which part requires better testing.

What better testing would look like

The tattoo industry does not need another hundred testimonials claiming a numbing product “worked.” It needs controlled, tattoo-relevant questions.

A meaningful study would compare the exact finished formula with a vehicle control and evaluate:

• reported pain at defined intervals;
• onset and duration;
• artist-rated skin texture and stretch;
• stencil transfer and retention;
• bleeding and visible edema;
• number of passes required for defined saturation;
• session interruptions and client movement;
• immediate irritation;
• standardized recovered-tattoo photography;
• touch-up requirement after an appropriate interval;
• differences by placement, skin type and technique.

Color packing and black-and-gray work should be analyzed separately—not because pigment color necessarily interacts with lidocaine, but because the procedures can place different mechanical demands on the skin.

Until that work exists, “ink-safe” should be treated as a claim requiring substantiation, not an industry synonym for “contains lidocaine.”

What artists and clients should ask

Clients

• Does my artist permit a numbing product?
• Which exact product and application method do they accept?
• Is it intended for intact skin only?
• How much can be used, over what area and for how long?
• Am I using another product that contains lidocaine?
• Do I have a history of reactions to anesthetics or formula ingredients?
• What should I do if the skin becomes red, swollen, itchy or blistered before the appointment begins?

Artists

• Can the client identify the exact product and Drug Facts label?
• Is the product lawfully labeled in this market?
• Was it applied only under its labeled conditions?
• Has all residue been removed before skin preparation?
• Does the skin look and feel workable?
• Is the client showing any reaction before the procedure begins?
• Is the client expecting “pain-free” or a guaranteed duration the product cannot promise?

Frequently asked questions

Does tattoo numbing cream really work?

Topical lidocaine can reduce superficial procedural pain, but effectiveness varies by formula, dose, contact time, body location and individual response. It should be described as temporary pain relief—not a guarantee of a painless tattoo.

Does numbing cream affect tattoo ink?

There is insufficient direct clinical evidence to say that every product is neutral or harmful to tattoo performance. Artists sometimes report changes in skin texture, swelling, residue or workability. Those effects may depend on the complete formula and application method rather than lidocaine alone.

Can numbing cream make it harder to pack color?

It may make work more difficult if the skin becomes swollen, overhydrated, irritated or hard to stretch. There is no controlled evidence proving that compliant topical lidocaine universally prevents color saturation. Better client stability may also help an artist work. Discuss the exact product with the artist.

Is numbing more useful for color than black-and-gray?

Not inherently. Color work may involve repeated passes for saturation, but black-and-gray styles can also require long, technically demanding sessions. Placement, technique, duration and personal sensitivity are more informative than pigment color alone.

What percentage of lidocaine is legal over the counter?

Under the U.S. OTC external-analgesic monograph, lidocaine is permitted within specified conditions up to 4%. A 4% concentration does not by itself establish compliance; the formula, claims, label and conditions of use must also conform.

Is 5% lidocaine better than 4%?

Not as a safe consumer assumption. FDA has issued warning letters involving 5% lidocaine products marketed for tattooing and other cosmetic procedures. Higher concentration does not answer questions about delivery, total exposure, safety or legal status.

Can a numbing spray be used after tattooing begins?

Do not assume so. Application to barrier-disrupted skin changes absorption and risk. Use must follow the exact product label and professional guidance. Our safety direction is intact-skin use before tattooing, not routine application to broken skin.

Why do some artists refuse numbing products?

Artists may have experienced altered texture, swelling, inconsistent client application, stencil issues, reactions or unrealistic expectations. Their process and risk tolerance deserve respect. Discuss numbing before the appointment rather than arriving with an unknown product already applied.

Does covering numbing cream make it work better?

Covering can increase absorption, which can increase both effect and risk. FDA specifically warns against covering topical pain products in ways that raise systemic exposure. Follow the exact Drug Facts directions; do not improvise with plastic wrap, heat or extended time.

The conclusion

The tattoo industry has spent years arguing whether numbing is good or bad.

That is the wrong level of analysis.

A topical anesthetic can reduce pain. A client who moves less may be easier to tattoo. A poor formula or poor application can irritate the skin, leave residue or change the working surface. A higher concentration can create more risk without proving a better tattoo. An artist can observe a real problem without that observation becoming a universal scientific law. A product can sell globally and still be noncompliant.

The serious position is not pro-numbing or anti-numbing.

It is pro-evidence, pro-transparency and pro-professional judgment.

Comfort is a legitimate goal. So is protecting the quality of the work. The standard should be a product and protocol capable of respecting both.

Editorial note: This article provides general educational and regulatory information, not medical or legal advice. Laws and product classifications vary by jurisdiction and can change. Follow the Drug Facts label for the exact product, and discuss numbing with your artist before the appointment. Market-report summaries were reviewed only as directional evidence of demand; no unaudited sales figure is presented as fact.

Sources

• U.S. Food and Drug Administration. FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects. March 26, 2024.
• U.S. Food and Drug Administration. Warning letter to a tattoo-numbing product seller. March 25, 2024.
• U.S. Food and Drug Administration. Warning letter concerning 5% lidocaine products with tattoo indications. February 25, 2025.
• U.S. Food and Drug Administration. OTC Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use.
• Eidelman A, Weiss JM, Lau J, Carr DB. Topical anesthetics for dermal instrumentation: a systematic review of randomized, controlled trials. Annals of Emergency Medicine. 2005;46(4):343–351.
• Jones SK, Handfield-Jones S, Kennedy CTC. Does EMLA reduce the discomfort associated with local-anaesthetic infiltration? Clinical and Experimental Dermatology. 1990;15(3):177–179.
• Metzler-Wilson K, Wilson TE. Topical anaesthesia does not affect cutaneous vasomotor or sudomotor responses in human skin. Autonomic & Autacoid Pharmacology. 2013;33(3–4):25–33.
• Kumar M, Chawla R, Goyal M. Topical anesthesia. Journal of Anaesthesiology Clinical Pharmacology. 2015;31(4):450–456.
• Serup J, et al. Esthetic and medical tattooing: Part I — Tattooing techniques, implications, and adverse effects. 2024.
• Miao Y, et al. Is Tattooing an Injection? Evaluating the Mechanics of Ink Placement. 2025.
• European Parliament and Council. Regulation (EC) No 1223/2009 on cosmetic products.

Continue exploring

Are we asking too much of tattoo artists? →
Vegan, natural, organic, clean: what those words mean on an ink label →
What actually matters the week before a tattoo →
03 · The Product — what goes on or into the skin →
04 · The Craft — how tattooing is performed and experienced →